Agreements

Theradiag, a company specializing in theranostics and in vitro diagnostics, has announced that it is significantly strengthening its activities in microRNA. Theradiag has signed a partnership agreement with the Regional Cancer Institute of Montpellier (ICM) to develop microRNA-based theranostics tools for the screening and monitoring of colorectal cancer. The goal of the collaborative R&D program called miCRA is to assess the expression and predictive role of microRNA in treatment response to radio/chemotherapies for colorectal cancer. As part of the project, Theradiag will identify relevant biomarkers and develop related theranostic assays.